asfasfasfasfsafasfasfasvas III, kontrollü, çift kör, çok merkezli çalışmada, otolog kök hücre nakli (ASCT) sonrasında en azından stabil hastalık (SD) elde eden yeni teşhis edilmiş multipl miyelom hastaları; nüksetmeye kadar REVLIMID® (lenalidomid) 10 mg (gerektiğinde 5 ya da 15 mg’ye artırma ya da düşürme; n=231) ya da plasebo (n=229) ile sürekli günlük tedavi almak üzere randomize edildi 2009 yılı Kasım ayında planlanan bir ara analizin Bağımsız Veri ve Güvenlik İzleme Komitesi raporu, çalışmanın birincil son noktayı karşıladığının ve 2009 Aralık ayında erken durdurulmasının ve körlükten

21. CRISPR Cas9 technology is arguably one of the greatest breakthroughs in modern medicine. It became popular in the scientific
community for being quicker, cheaper, more accurate, and efficient than other genetic engineering methods. As of June 2020,
more than USD 3.2 Bn has been invested in CRISPR startups, of which many have gone public over the last five years.

23. Examples of CRISPR startups in this space include:
Mammoth Biosciences, which has created the first CRISPR-mediated platform for human disease detection.
Caseiba Therapeutics is another startup in this category that’s focused on finding treatments for inherited diseases like hemophilia.

24. According to a study by Netscribes, the funding for CRISPR
startups has grown by 69% CAGR over the last four years from
2016-2019.
2019 was a great year for CRISPR startups in terms of fundings
received,
Poseida Therapeutics being at the forefront of that list (through
series C funding of USD 142 mn).
Beam Therapeutics was a close second with its series B funding
of USD 135 mn, and Inscripta came third with its series D
funding of USD 125 mn.
Biomedical R&D
CURES for diseases like:
Cancer,
Genetic Blindness,
AIDS,
Cystic Fibrosis,
Muscular Dystrophy,
Huntington’s disease.

25. Some of the largest investors in this field include Arch Venture Partners, Fidelity Management & Research Company, GV (formerly
Google Ventures), and Alexandria Venture Investments.

27. 1. Inscripta
Specialization: CRISPR-associated natural and synthetic nucleases
2. Inari Agriculture
Specialization: Plant-breeding
3. Synthego
Specialization: Genetic engineering solutions that bring precision and automation to genome editing
4. KSQ Therapeutics
Specialization: Transformative medicines
5. eGenesis
Specialization: CRISPR-based Xenotransplantation
6. Verve Therapeutics
Specialization: Cardiovascular and coronary artery diseases
7. Tango Therapeutics
Specialization: Novel medicines targeting cancer vulnerabilities

29. Top CRISPR Startup Companies Changing the Future of Biotech
and Medicine
Mammoth Biosciences: Using CRISPR to Advance Clinical
Diagnostics.
Inscripta Therapeutics: Increasing CRISPR's Reach.
eGenesis: Using CRISPR to Improve Organ Transplants.
Synthetic Genomics: Harnessing CRISPR to Create Sustainable
Energy.
The Top 7 Pharmaceutical Stocks for the Next 10 Years
(11 Jan 2021)
Pfizer (NYSE:PFE)
Bristol-Myers Squibb (NYSE:BMY)
AbbVie (NYSE:ABBV)
Sanofi (NYSE:SNY)
Takeda (NYSE:TAK)
Novartis (NYSE:NVS)
Johnson & Johnson (NYSE:JNJ)

30. Bayer and CRISPR Therapeutics joined hands in 2016 and founded their new gene-editing venture Caseiba Therapeutics. Vertex
Pharmaceuticals acquired Exonics Therapeutics in 2019 for USD 245 mn. In the same year, the parent company of Juno
Therapeutics, Celgene, was acquired by Bristol-Myers Squibb.
Other leading pharma investors in this field include:
AstraZeneca (AZ),
Novartis, GlaxoSmithKline (GSK),
AbbVie,
Eli Lilly,
Pfizer,
Roche,
and Johnson & Johnson.

67. Connections